

Cost-Benefit/Cost-Effectiveness
Research of Drug Abuse
Prevention: Implications for
Programming and Policy

Editors:

William J. Bukoski, Ph.D.

Richard I. Evans, Ph.D.

NIDA Research Monograph 176
1998

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

National Institute on Drug Abuse
Division of Epidemiology and Prevention Research
5600 Fishers Lane
Rockville, MD 20857

ACKNOWLEDGMENT

This monograph is based on the papers from a technical review on “Cost-Benefit/Cost-Effectiveness Research of Drug Abuse Prevention: Implications for Programming and Policy” held on July 28-29, 1994. The review meeting was sponsored by the National Institute on Drug Abuse.

COPYRIGHT STATUS

The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder's permission is required. All other material in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors. Citation of the source is appreciated.

Opinions expressed in this volume are those of the authors and do not necessarily reflect the opinions or official policy of the National Institute on Drug Abuse or any other part of the U.S. Department of Health and Human Services.

The U.S. Government does not endorse or favor any specific commercial product or company. Trade, proprietary, or company names appearing in this publication are used only because they are considered essential in the context of the studies reported herein.

National Institute on Drug Abuse
NIH Publication No. 98-4021
Printed June 1998

NIDA Research Monographs are indexed in the *Index Medicus*. They are selectively included in the coverage of *American Statistics Index*, *BioSciences Information Service*, *Chemical Abstracts*, *Current Contents*, *Psychological Abstracts*, and *Psychopharmacology Abstracts*.

Table of Contents

Click on the title or the page number to go to section

Introduction.....	1
<i>William J. Bukoski</i>	
The Impact of Substance Abuse on Federal Spending.....	5
<i>Jeffrey Merrill and Kimberley Fox</i>	
A Historical Perspective on Effective Prevention.....	37
<i>Richard I. Evans</i>	
School-Based Approaches to Drug Abuse Prevention: Evidence for Effectiveness and Suggestions for Determining Cost-Effectiveness.....	59
<i>Gilbert J. Botvin, Elizabeth M. Botvin, and Hirsch Ruchlin</i>	
Effectiveness of Prevention Interventions With Youth at High Risk of Drug Abuse.....	83
<i>Richard F. Catalano, Kevin P. Haggerty, Randy R. Gainey, Marilyn J. Hoppe, and Devon D. Brewer</i>	
Costs, Benefits, and Cost-Effectiveness of Comprehensive Drug Abuse Prevention.....	111
<i>Mary Ann Pentz</i>	
Overview of Methods: Cost-Effectiveness, Cost-Benefits, and Cost-Offsets of Prevention.....	130
<i>Albert Woodward</i>	
Analytic Issues for Estimating the Benefits and Costs of Substance Abuse Prevention.....	141
<i>Gary A. Zarkin and Robert L. Hubbard</i>	
Benefits and Costs of a Family-Focused Methadone Treatment and Drug Abuse Prevention Program: Preliminary Findings.....	161
<i>Robert D. Plotnick, Diane S. Young, Richard F. Catalano, and Kevin P. Haggerty</i>	

Issues and Methods in Evaluating Costs, Benefits, and Cost-Effectiveness of Drug Abuse Prevention Programs for High-Risk Youth.....	184
<i>Marsha Lillie-Blanton, Lisa Werthamer, Pinka Chatterji, Claire Fienson, and Christine Caffray</i>	
Implications for Prevention Policy: A Commentary.....	214
<i>Robert L. DuPont</i>	